Clario and Strados Labs partner to bring new pulmonary endpoints to respiratory clinical trials
Clario has partnered with Strados Labs to offer its customers the RESP™ Biosensor System, an advanced technological innovation for the at-home capture of lung sounds. The revolutionary device enables Clario to support the capture of additional clinical respiratory endpoints such as cough and wheeze, and it does so in a patient-friendly, streamlined way.
Senzo and Abingdon Health Enter Into Strategic Partnership
Abingdon Health’s CDMO service to support Senzo in leveraging its innovative, high-accuracy Amplified Lateral Flow (ALF) point-of-care diagnostics platform technology across multiple product opportunities.
Palvella Therapeutics Announces Positive Topline Results from Phase 2 Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations, a Serious, Rare Genetic Skin Disease with No FDA-approved Therapies
– QTORIN™ rapamycin generally well-tolerated; no drug related severe adverse events and no observed rapamycin in systemic circulation
– 100% of participants were either “Much Improved” or “Very Much Improved” as rated by the Clinician Global Impression of Change following 12-weeks of QTORIN™ rapamycin
– End of Phase 2 meeting completed with U.S. Food and Drug Administration in February 2023; pending additional interactions with FDA, anticipate potential initiation of pivotal Phase 3 study in second half of 2023
– FDA previously granted Fast Track Designation and Orphan Drug Designation to QTORIN™ rapamycin for Microcystic Lymphatic Malformations
– QTORIN™ rapamycin has potential to become first therapy and standard of care for the estimated more than 30,000 individuals with Microcystic Lymphatic Malformations in U.S., if approved
VESTECK, Inc. is pleased to announce the first in human use of several SUTURE-TIGHT devices
Venatorx Pharmaceuticals Appoints Tomas J. Heyman as Non-Executive Chairman
Dr. Michael Diem Steps Down from Board of Directors
Hanimune Therapeutics raises $3.3M, sets sights on first food allergy treatment product
Palvella Therapeutics Announces Pipeline Update on QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ Rapamycin) for Serious, Rare Genetic Skin Diseases with No FDA-approved Therapies
– Pivotal Phase 3 data for the treatment of Pachyonychia Congenita anticipated mid-2023 –
– Phase 2 data for the treatment of Microcystic Lymphatic Malformations anticipated March 2023 –
– Phase 2b data for the prevention of Basal Cell Carcinomas in patients with Gorlin Syndrome anticipated 2Q 2023 –
Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board
Advisory board to help guide selection of novel antibody-target pairs for ADC and T cell redirection modalities